- Substantial Pre-Seed Funding: Somite has secured $5.3M in pre-seed funding, led by TechAviv and supported by multiple notable venture firms, to advance their AlphaStem AI platform.
- Innovative AI Application in Stem Cell Biology: The company is developing AI models for stem cell biology, specifically targeting large-scale human tissue production for cell therapies for diseases like diabetes and muscular dystrophies.
- Development of a Digital Twin for Embryos: Somite is pioneering a digital twin of the embryo to enhance AI-driven cell therapy development, utilizing advanced data analysis from sources like scRNA-Seq and gene expression databases.
Impact
- Acceleration of Cell Therapy Research: The funding will boost the development of AI-driven technologies, potentially speeding up breakthroughs in cell therapies for complex diseases.
- Attracting Investor Interest: The innovative approach and significant early funding may draw more investors to the emerging field of AI in biotechnology.
- Enhancement of Biotechnological Capabilities: The development of a digital twin model could set new standards for precision in biotechnology, influencing future research and applications.
- Potential for Significant Medical Advancements: Somite’s technology could lead to substantial advancements in treating diseases with currently limited options, impacting patient care and health outcomes.
- Strengthening of Academic and Commercial Ties: Collaborations with prominent academic figures and institutions could enhance the credibility and commercial viability of Somite’s research.
Eksentricity 
Leave a comment